Asher Bio Raises $108m For Immune Cell-Specific Therapies
Series B Follows $55m Series A Round In March
With a CD8-targeting IL-2 mutein as its lead program, the start-up is developing cis-targeted immunotherapies that selectively target two molecules on the same immune cell for improved efficacy and safety.
